Breadth and depth of cancer portfolio data
That does speak to the breadth of the portfolio, but also the depth and quality of the data that we’re presenting
at ESMO congress in Madrid
S
Susan GalbraithAstraZeneca · Executive
On the same topic: Biotech & medicine
More →“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”